Understanding the binding of 5-substituted 2′-deoxyuridine substrates to thymidine kinase of herpes simplex virus type-1

Journal of Medicinal Chemistry

Volumn 39, Issue 24, 1996, Pages 4727-4737

  De Winter, Hans ^a   Herdewijn, Piet ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (PYRROL 1 YL) 2' DEOXYURIDINE; ANTIVIRUS AGENT; IDOXURIDINE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; ENZYME INHIBITION; HERPES SIMPLEX VIRUS 1; MATHEMATICAL ANALYSIS; MOLECULAR INTERACTION; QUANTITATIVE DIAGNOSIS; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; BINDING SITES; DEOXYURIDINE; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SIMPLEXVIRUS; SUBSTRATE SPECIFICITY; THERMODYNAMICS; THYMIDINE KINASE;

EID: 0030446499     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960278v     Document Type: Article

References (31)

1. Prusoff, W. H. Synthesis and biological activity of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta 1959, 32, 295-296.
2. Herdewijn, P. A. M. M. 5-Substituted-2′-deoxyuridines as anti-HSV-1 agents: synthesis and structure activity relationship. Antiviral Chem. Chemother. 1994, 5, 131-146.
3. De Clercq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A. S.; Walker, R. T. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2947-2951.
4. Spadari, S.; Maga, G.; Focher, F.; Ciarrocchi, G.; Manservigi, R.; Arcamone, F.; Capobianco, M.; Carcuro, A.; Colonna, F.; Iotti, S; Garbesi, A. L-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth. J. Med. Chem. 1992, 35, 4214-4220.
5. Coen, D. M. The implications of resistance to antiviral agents for herpes virus drug targets and drug therapy. Antiviral Res. 1991, 15, 287-300.
6. Coen, D. M.; Kosz-Vnenchak, M.; Jacobson, J. G.; Leib, D. A.; Bogard, C. L.; Schaffer, P. A.; Tyler, K. L.; Knipe, D. M. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 4736-4740.
7. Brown, D. G.; Visse, R.; Sandhu, G.; Davies, A.; Rizkallah, P. J.; Melitz, C.; Summers, W. C.; Sanderson, M. R. Crystal structures of the thymidine kinase from herpes simplex virus type-I in complex with deoxythymidine and Ganciclovir. Nature Struct. Biol. 1995, 2, 876-881.
8. Wigerinck, P.; Pannecouque, C.; Snoeck, R.; Claes, P.; De Clercq, E.; Herdewijn, P. 5-(5-Bromothien-2-yl)-2′-deoxyuridine and 5-(5-chlorothien-2-yl)-2′-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2′-deoxyuridine in the inhibition of herpes simplex virus type I replication. J. Med. Chem. 1991, 34, 2383-2389.
9. Wigerinck, P.; Snoeck, R.; Claes, P.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 5-heteroaryl-substituted-2′-deoxyuridines. J. Med. Chem. 1991, 34, 1767-1772.
10. Wigerinck, P.; Kerremans, L.; Claes, P.; Snoeck, R.; Maudgal, P.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 5-(thien-2-yl)-2′-deoxyuridine analogues. J. Med. Chem. 1993, 36, 538-543.
11. Olivier, A.; Creuven, I.; Evrard, C.; Evrard, G.; Dory, M.; Van Aerschot, A.; Wigerinck, P.; Herdewijn, P.; Durant, F. Stereoelectronic properties of five anti-HSV-1 2′-deoxynucleosides analogues with heterocyclic substituents in the 5-position: A comparison with BVDU. Antiviral Res. 1994, 24, 289-304.
12. Creuven, I.; Evrard, C.; Evrard, G.; Wigerinck, P.; Herdewijn, P.; Durant, F. Relationship between structural properties and affinity for HSV-1 kinase of bromine substituted 5-heteroaromatic 2′-deoxyuridines. Antiviral Res. 1996, 30, 63-74.
13. Creuven, I.; Evrard, C.; Evrard, G.; Wigerinck, P.; Herdewijn, P.; Durant, F. Crystal structure of 5-(thien-2-yl)uracil analogues: 5-(5-methylthien-2-yl)-2′-deoxyuridine, 5-(5-chlorothien-2-yl)-2′-deoxyuridine and 5-(5-bromothien-2-yl)-2′-deoxyuridine. J. Chem. Cryst., in press.
14. Creuven, I.; Lebon, F.; Busson, R.; Herdewijn, P.; Durant, F. Structural study of two 5-heteroaromatic-2′-deoxyuridines and their bromine analogues: theoretical conformational analysis and NMR experiments. Manuscript in preparation.
15. Luyten, I.; De Winter, H.; Busson, R.; Lescrinier, T.; Creuven, I.; Durant, F.; Balzarini, J.; De Clercq, E.; Herdewijn, P. Synthesis of 5-(isothiazol-5-yl)-2′-deoxyuridine and its interaction with the HSV-1 thymidine kinase. Helv. Chim. Acta 1996, in press.
16. Parkanyi, L.; Kalman, A.; Czugler, M.; Kovacs, T.; Walker, R. T. A comparison of the conformations adopted by some 5-bromovinyl-2′-deoxyuridines and a correlation with their antiviral properties: an X-ray study. Nucleic Acids Res. 1987, 15, 4111-4121.
17. Balzarini, J.; Bohman, C.; De Clercq, E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of Herpes Simplex virus type 1 or type 2. J. Biol. Chem. 1993, 268, 6332-6337.
18. Bohman, C.; Balzarini, J.; Wigerinck, P.; Van Aerschot, A.; Herdewijn, P.; De Clercq, E. Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of Herpes Simplex virus. J. Biol. Chem. 1994, 269, 8036-8043.
19. Davis, M. E.; McCammon, J. A. Electrostatics in biomolecular structure and dynamics. Chem. Rev. 1990, 90, 509-521.
20. Sitkoff, D.; Sharp, K. A.; Honig, B. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 1994, 98, 1978-1988.
21. Ben-Naim, A.; Marcus, Y. Solvation thermodynamics of nonionic solutes. J. Chem. Phys. 1984, 81, 2016-2027.
22. Honig, B.; Gilson, M. K. Calculation of the total electrostatic energy of a macromoleular system: solvation energies, binding energies, and conformational analysis. Proteins 1988, 4, 7-18.
23. Honig, B.; Sharp, K.; Yang, A.-S. Macroscopic models of aqueous solutions: biological and chemical applications. J. Phys. Chem. 1993, 97, 1101-1109.
24. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all-atom force field for simulations of proteins and nucleic acids. J. Comput. Chem. 1986, 7, 230-252.
25. McDonald, I. K.; Thornton, J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 1994, 238, 777-793.
26. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440.
27. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graph. 1988, 6, 13-27.
28. Kraulis, P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.
29. Singh, U. C.; Kollman, P. A. An approach to computing electrostatic charges for molecules. J. Comput. Chem. 1984, 5, 129-145.
30. De Winter, H. L; von Itzstein, M. Aldose reductase as a target for drug design: molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme. Biochemistry 1995, 34, 8299-8308.
31. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General atomic and molecular electronic structure system. J. Comput. Chem. 1993, 14, 1347-1363.